This content is machine translated Diffuse large B-cell lymphoma T-cell-based therapy “off the shelf” Two types of T-cell-based therapy are available for refractory or relapsing diffuse large B-cell lymphoma (DLBCL): CAR T cells and bispecific antibodies. While CAR T cells have revolutionized individualized medicine…
View Post 7 min This content is machine translated Hematology Blood, blood cells, blood diseases – current research at a glance The most important European meeting of hematologists is held annually in June. Renowned experts will gather at the EHA Annual Congress to present and discuss current research data on various…
View Post 3 min This content is machine translated Cancer medicine of the future Car-T cell therapy and its application in practice CAR-T cell technology is considered the latest achievement in cancer medicine. The first approvals in Europe took place in mid-2018 – Switzerland followed at the end of 2018. Currently, the…
View Post 4 min This content is machine translated Hemato-Oncology All hopes lie in targeted therapy What do so-called targeted therapies actually aim at? And what progress has been made in the various hematologic oncologic neoplasms in this regard? At the 21st Symposium Medicine in the…
View Post 4 min This content is machine translated Lymphomas What the family doctor needs to know At the SGIM Great Update in Interlaken, the most common problems and challenges that a family physician encounters when dealing with patients suffering from lymphoma were discussed. The only difficulty…
View Post 6 min This content is machine translated Chronic lymphocytic leukemia and non-Hodgkin's lymphoma Updates on the active ingredients GA101 and rituximab Three studies on chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma were discussed at the ASH in New Orleans: One was an update on the stage 1 analysis of the CLL11…
View Post 4 min This content is machine translated HER2-positive breast cancer and lymphoma New applications and antibodies The antibody-drug conjugate trastuzumab emtansine, T-DM1 (Kadcyla®), is composed of the antibody trastuzumab and the chemotherapeutic agent DM1 and is currently being investigated for the treatment of HER2-positive cancers. It…
